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Patients with multiple comorbidities are often administered simultaneously or
sequentially antifungals and antibacterial agents, without full knowledge of the
consequences of drug interactions. Considering the clinical relevance of liposomal
amphotericin B (L-AMB), the association between L-AMB and six antibacterial agents
was evaluated against four clinical isolates and one type strain of Candida spp. and two
clinical isolates and one type strain of Aspergillus fumigatus. In order to evaluate such
combined effects, the minimal inhibitory concentration (MIC) of L-AMB was determined
in the presence of 0.5-, 1-, 2-, and 4-fold peak plasma concentrations of each of the
antibacterial drugs. Since the L-AMB/colistin (CST) association was the most synergic,
viability assays were performed and the physiological status induced by this association
was characterized. In addition, computational molecular dynamics studies were also
performed in order to clarify the molecular interaction. The maximum synergistic effect
with all antibacterial agents, except CST, was reached at fourfold the usual peak plasma
concentrations, resulting in 2-to 8-fold L-AMB MIC reduction for Candida and 2-to 16-
fold for Aspergillus. For CST, the greatest synergism was registered at peak plasma
concentration (3 mg/L), with 4-to 8-fold L-AMB MIC reduction for Candida and 16-to
32-fold for Aspergillus. L-AMB at subinhibitory concentration (0.125 mg/L) combined
with CST 3 mg/L resulted in: a decrease of fungal cell viability; an increase of cell
membrane permeability; an increase of cellular metabolic activity soon after 1 h of
exposure, which decreased until 24 h; and an increase of ROS production up to 24 h.
From the molecular dynamics studies, AMB and CST molecules shown a propensity
to form a stable molecular complex in solution, conferring a recognition and binding
added value for membrane intercalation. Our results demonstrate that CST interacts
synergistically with L-AMB, forming a stable complex, which promotes the fungicidal
activity of L-AMB at low concentration.
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INTRODUCTION
Fungi are recognized as major pathogens in critically ill patients.
Candida and Aspergillus species are the most common agents
of invasive fungal infections (IFIs), although other yeasts and
filamentous fungi are becoming emerging pathogens (Gullo,
2009). In the clinical practice, patients at risk for IFIs often
receive concomitantly or sequentially antifungal therapy and
antibacterial agents, either for prophylactic or therapeutic
purposes (Stergiopoulou et al., 2009). However, this procedure
is often adopted without full knowledge of the consequences
resulting from pharmacological drug interactions.
A recent literature review showed that the combination of
amphotericin B (AMB) or fluconazole with antibacterial agents
that impair RNA or protein synthesis, such as rifampicin (RIF),
azithromycin (AZM), clarithromycin (CLR), and tetracycline
(TET), enhances the in vitro activity of the antifungal agent
against yeast and filamentous fungi (Azevedo et al., 2015).
In addition, Zeidler et al. (2013) demonstrated that colistin
(CST), an antibiotic that targets Gram-negative membranes,
exhibits a synergistic effect with antifungal agents belonging
to the echinocandin class against Candida spp. According to
the authors, the echinocandin weakens the fungal cell wall
facilitating the colistin action upon fungal membranes, and,
consequently, this effect enhances the antifungal activity of the
echinocandin (Zeidler et al., 2013). These results are particularly
promising since the available antifungal panoply is narrow,
encompassing only a few classes of agents, and the discovery of
new drugs is a slow and exhaustive process (Roemer and Boone,
2013). Moreover, some antifungals demonstrate limited efficacy,
high toxicity, and are prone to the development of antifungal
resistance. Therefore, the association of compounds that enhance
the efficacy of antifungal drugs may contribute to a more effective
reduction of fungal burden and minimize the development of
resistance (Zeidler et al., 2013).
Although the association of antifungal and antibacterial agents
may have beneficial implications in clinical terms, little is known
about the pharmacological drug interactions and the underlying
mechanisms of synergism. While there are few studies available
addressing this topic, it is important to stress that antagonistic
or indifferent effects may also be found (Petrou and Rogers,
1988; Stergiopoulou et al., 2009; Venturini et al., 2011). Thus, an
extensive study aiming to evaluate the mechanisms involved in
the association between antifungal and antibacterial agents upon
fungal growth inhibition is mandatory.
We hereby propose to evaluate the association between
liposomal amphotericin B (L-AMB) and several antibacterial
drugs against Candida spp. and Aspergillus fumigatus, as well
as to unveil the mechanisms underlying such drug interactions.
In the case of synergistic interaction, we have investigated
using molecular dynamics (MD) simulations whether (i) the
antibacterial agent has an intrinsic activity upon fungal cells;
or (ii) the antibacterial agent acts as a facilitator of AMB
activity. MDs simulations have been widely applied to study
the interaction of AMB molecules with the fungal membranes,
since the mechanism of action of AMB is not well characterize
(Baginski et al., 1997; Sternal et al., 2004; Czub and Baginski,
2006; Czub et al., 2007; Neumann et al., 2009; Cohen, 2010; Foglia
et al., 2014). Thus, this approach may be essential to unveil the
mechanism of synergism.
Our results demonstrate which antibacterial agents improve
L-AMB efficacy and elucidate about the hypothetical underlying
mechanism.
MATERIALS AND METHODS
Strains and Growth Conditions
Four Candida clinical isolates and one type strain (C. albicans
596, C. albicans 38, C. glabrata 590, C. krusei 120, and C. albicans
ATCC 90028) and two clinical isolates and one type strain of
A. fumigatus (A. fumigatus 76, A. fumigatus 88, and A. fumigatus
ATCC MYA-3626) were used in this study. Clinical isolates of
Candida spp. and A. fumigatus were obtained from patients
admitted at Centro Hospitalar São João, Porto, Portugal. Isolates
are included in the Collection of fungal clinical isolates deposited
at Department of Microbiology, Faculty of Medicine of Porto,
Portugal. Candida isolates were grown in Sabouraud dextrose
agar (SDA; Formedium, Norfolk, United Kingdom) at 35◦C
for 24 h (Teixeira-Santos et al., 2012); Aspergillus isolates were
cultured in SDA at 35◦C for 72 h (Faria-Ramos et al., 2014).
Escherichia coli ATCC 25922 was also included in this study for
control of antibacterial drugs.
Antimicrobial Drugs and Susceptibility
Testing
Liposomal amphotericin B (provided by Gilead Sciences, Inc,
San Dimas, CA, USA), rifampicin (Sanofi Aventis, Anagni,
Italy), azithromycin (Farmoz, Sintra, Portugal), clarithromycin
(Alcala Farma, Madrid, Spain), colistin sulfate salt (C4461,
Sigma–Aldrich, Munich, Germany), tetracycline (T3258, Sigma–
Aldrich), and linezolid (LZD; Pfizer, New York, NY, USA), were
prepared according to the manufacturer’s guidelines, in order
to obtain stock solutions of 2 mg/L. The minimal inhibitory
concentration (MIC) of L-AMB was determined according to
M27-A3 protocol and M27-S4 supplement for Candida sp. and
M38-A2 protocol of Clinical and Laboratory Standards Institute
for Aspergillus sp. (CLSI, 2008a,b, 2012). The MIC of each
antibacterial drugs was also determined; the tested antibacterial
concentrations ranged between 0.25 and 128 mg/L. In order to
evaluate the effect between L-AMB and the different antibacterial
agents, the MIC to L-AMB was determined in the presence
of 0.5-, 1-, 2-, and 4-fold peak plasma concentrations of each
antibacterial drug. Peak plasma levels described in the literature
are: RIF 12 mg/L (Van Ingen et al., 2011), AZM 4 mg/L (Sevillano
et al., 2006), CLR 2 mg/L (Kees et al., 1995), CST 3 mg/L
(Michalopoulos and Falagas, 2011), TET 2 mg/L (Agwuh and
MacGowan, 2006), and LZD 12 mg/L (Dryden, 2011). Briefly, the
drugs were diluted twofold in culture medium in order to obtain
a 1:4 dilution. Fifty microliters of each L-AMB concentration
(ranging from 0.03 to 16 mg/L) were combined with 50 µL
of each of the concentration of the distinct antibacterial agents
(described above). The plates were incubated at 35◦C and the
L-AMB MIC values determined after 24 and 48 h; MIC was
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the lowest concentration that prevented any discernible growth.
Since clinical breakpoints were not yet established for L-AMB,
the Candida isolates were classified in wild type (wt) whenever
the MIC was ≤2 mg/L and non-wild type (nwt) when the
MIC was >2 mg/L according to the epidemiological cutoff
values (ECVs) proposed by Pfaller and Diekema (2012). For
A. fumigatus, only the MIC value is displayed, since AMB ECVs
and clinical breakpoints remain undefined (Pfaller and Diekema,
2012). C. albicans ATCC 90028 and A. fumigatus ATCC MYA-
3626 type strains were used as controls, as recommended by CLSI
protocol (CLSI, 2008a,b, 2012). E. coli ATCC 25922 was used as
a bacterial quality control to assure that antibacterial dilutions
were correct. MIC determination assays were performed in
triplicate.
Evaluation of Cell Viability
The evaluation of cell viability was performed with C. albicans
596, as a representative example, for the most synergic
association, L-AMB/CST. The concentrations tested were
selected according the susceptibility results. Yeast suspensions
(106 yeast cells/mL) were exposed to L-AMB 0.125 mg/L
alone and in combination with CST 3 mg/L, for 24 h at 35◦C,
150 rpm. Another suspension was prepared and treated with
single CST 3 mg/L. At specific time points, 1, 3, 6, and 24 h,
aliquots were collected and tested for viability. Cell viability
was determined in triplicate by counting colony forming units
(CFU). Briefly, the number of viable cells for each treatment
was determined by plating 100 µL of serial dilutions on SDA
agar medium and incubating at 35◦C for 24 h; the number of
CFUs was determined and compared with control plates (not
exposed to drugs or exposed to each antimicrobial drug, L-AMB
and CST); before being plated, cells were washed once and
resuspended in fresh medium in order to prevent antifungal
carryover.
Functional Characterization of Drug
Interaction
The distinct cellular physiological status resulting from the
interaction between L-AMB and CST were assessed by flow
cytometry in a time-course assay, using C. albicans 596 as a
representative example. A cell suspension (106 yeast cells/mL)
was used in all assays described below. Yeast cells were incubated
with single L-AMB 0.125 mg/L and in association with CST
3 mg/L during 24 h. In order to evaluate whether there was
a CST concentration-dependent effect, the following treatment
conditions were also tested: L-AMB 0.125 mg/L with (i) CST
1.5 mg/L and (ii) CST 6 mg/L. The cellular status induced by
single CST treatment was evaluated as control. At specific time
points, 1, 3, 6, and 24 h, aliquots were collected and evaluated.
All cytometric evaluations were performed in a FACSCalibur
cytometer (BD Biosciences, Sydney, NSW, Australia) standard
model, equipped with three photomultipliers, standard filters, a
15-mW 488-nm Argon laser, and using CellQuest Pro software
(version 4.0.2). All the assays were performed in triplicate.
The effect of L-AMB 0.125 mg/L alone and in association with
CST 3 mg/L was evaluated regarding: (i) membrane potential, (ii)
membrane integrity, (iii) metabolic activity, and (iv) endogenous
reactive oxygen species (ROS) production.
Evaluation of Membrane Potential
The cell membrane potential was assessed by staining the
cells with Bis-(1,3-Dibutylbarbituric Acid) Trimethine Oxonol
(DiBAC4(3), Sigma–Aldrich), as described by Teixeira-Santos
et al. (2012). The fluorescence intensity (FI) at FL1 (fluorescent
detector; 530 nm) was registered and a staining index (SI) was
defined as the ratio between the FI of treated cells and the FI of
non-treated cells.
Evaluation of Membrane Integrity
Cell membrane integrity impairment was evaluated using
propidium iodide (PI, Sigma–Aldrich) staining. After
antimicrobial treatment, yeast cells were stained with 1 mg/L of
PI for 30 min at 35◦C, in the dark (Pina-Vaz et al., 2005). The FI
was measured at FL3 (fluorescent detector; 630 nm). The amount
of injured cells in each sample was defined as the percentage of
PI-positive cells.
Evaluation of Metabolic Activity
Metabolic changes were evaluated using 5-Carboxyfluorescein
diacetate (5-CFDA, Sigma–Aldrich), at 10 µM final
concentration. Antimicrobial treated cells were stained with
5-CFDA and incubated for 45 min, at 35◦C, at 150 rpm, in the
dark (Liao et al., 2003). The mean intensity of fluorescence (MIF)
was registered at FL1 (530 nm).
Evaluation of Endogenous ROS Production
Reactive oxygen species production was evaluated as previously
described (Yan et al., 2009). In brief, yeast cells were incubated
with 20 mg/L of 2′,7′-dichlorofluorescin diacetate (DCFH-DA,
Sigma–Aldrich) for 30 min at 35◦C, at 150 rpm. Cells were
washed once (2,655 × g for 5 min at room temperature;
5417R, Eppendorf) and resuspended in phosphate-buffered
saline (PBS, Sigma–Aldrich); afterward, cells were treated with
the antimicrobials as described in “Functional characterization of
drug interactions” section. FI was determined at FL1 (530 nm).
ROS production was calculated by subtracting the FI value
displayed by cells treated with antimicrobials from that of cells
treated with both antimicrobials and DCFH-DA.
Simultaneously, 10 µL of the treated cell suspension were
placed in a microscope slide for further analysis under
fluorescence microscopy, in a Carl Zeiss Axiovert inverted
microscope, using laser wavelength of 488 nm.
Molecular Dynamics Studies
The Automated Topology Builder (ATB) web server was used
for the AMB (C47H73NO17) and CST (C52H98N16O13) MDs
topology parametrization, corresponding to the new residues
name IDs D3JY and 09SS, respectively, as a GROMACS G54A7FF
United-Atom force field (Malde et al., 2011).
The ATB derived force-field was tested in a series of
independent MD simulations in an explicit water box. Then,
AMB and CST molecules were placed in the same simulation
box, together with 6230 SPCE water molecules, at more than
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17 Å apart from each other, in order to avoid any computational
bias. The entire MD protocol, including energy minimization,
equilibration, and production steps, were performed using
GROMACS 4.6.1 simulation package (Hess et al., 2008). MD
simulations were performed at the in-house Fermi GPU high
performance computing workstation. The global charge of the
system was zero and simulations run under periodic boundary
conditions in an isothermal-isobaric (NPT) ensemble at 300 K
and 1.0 bar, during 20 ns, as described in previous studies (Branco
et al., 2012).
Statistical Analysis
Results are detailed as mean value and the respective standard
deviation. Paired-sample Student’s t-test was used to compare the
effect of L-AMB and CST alone and in association.
All statistical analysis was performed using the SPSS software
(v. 23.0).
RESULTS
Susceptibility to L-AMB alone and in
Association with Antibacterial Drugs
Single RIF, AZM, CLR, CST, TET, and LZD did not inhibit the
growth of all the fungal species studied, even at the maximum
tested concentrations (fourfold peak plasma concentrations). The
fungal strains showed variable susceptibility profiles to L-AMB,
being all Candida strains wt (MIC value ≤ 1 mg/L), except
C. krusei with a MIC value of 8 mg/L. Regarding A. fumigatus
MIC values of 2 and 4 mg/L were registered (Table 1).
Minimal inhibitory concentration of L-AMB was reduced 2-
to 4-fold in the presence of peak plasma concentrations of RIF,
AZM, CLR, and TET. The maximum effect of these antibacterial
agents was obtained at fourfold plasma concentrations with
a reduction of L-AMB MIC of 2-to 8-fold, in the case of
Candida (except CLR regarding C. krusei 120) and 2-to 16-
fold for A. fumigatus (Table 1). CST at 0.5-fold peak plasma
concentration (1.5 mg/L) resulted in a reduction of L-AMB MIC
of 2-to 4-fold for all fungal isolates tested. At the peak plasma
concentration (3 mg/L), CST reduced L-AMB MIC in 4-to 8-fold
for Candida spp. and 16-to 32-fold for A. fumigatus. Interestingly,
CST at 2- and 4-fold peak plasma concentration (6 and 12 mg/L,
respectively) resulted in the same effect upon L-AMB MIC as CST
3 mg/L. Linezolid, even at fourfold peak plasma concentration
did not associate with any L-AMB MIC reduction, regarding all
tested fungal strains.
Colistin was selected for further studies since it was the drug
that exhibited the highest synergistic effects with L-AMB.
Impact of L-AMB/CST Association upon:
Fungal Cell Viability
Figure 1A represents C. albicans 596 viability at subinhibitory
concentration of L-AMB (0.125 mg/L), alone and in association
with CST 3 mg/L. Treatment with L-AMB 0.125 mg/L
significantly decreased yeast cell viability up to 3 h of exposure
(p = 0.039); however, after 3 h of treatment, cells recovered the
ability to replicate and viability increased up to 24 h. At this
time point, a significant difference was registered between cells
treated with L-AMB and non-treated cells (p= 0.011). In the case
of cells exposed to CST, significant growth reduction was only
registered after 24 h of incubation (p = 0.009). Whenever cells
were treated with L-AMB in association with CST there was a
significant reduction of CFU counts (107 to 105 cells/mL) soon
after 3 h of incubation (p = 0.037). This CFU reduction was
consistently observed along the time up to 24 h (p= 0.004).
Cell Membrane Permeability
Liposomal amphotericin B acts on fungal cells by binding to
the sterol component of the cell membrane, first leading to
alterations in cell permeability (Gray et al., 2012). In order
to evaluate whether antibacterial agents improve the effect
of L-AMB on cell membrane permeability, the membrane
potential and cell membrane integrity were assessed with the
fluorescent dyes DiBAC4(3) and PI, respectively. DiBAC4(3)
enters only in depolarized cells, where it binds reversibly to
intracellular components, resulting in an increased fluorescent
TABLE 1 | Minimal inhibitory concentration (MIC) of liposomal amphotericin B alone and in association with several antibacterial drugs at fourfold peak
plasma concentrations.
MIC value of L-AMB (mg/L)
Fungal isolates L-AMB in association with
L-AMB RIF AZM CLR CST TET LZD
C. albicans ATCC 90028 1 0.25 0.25 0.25 0.125 0.25 1
C. albicans 596 1 0.125 0.25 0.25 0.125 0.25 1
C. albicans 38 0.5 0.06 0.25 0.25 0.06 0.25 0.5
C. glabrata 590 0.25 0.125 0.125 0.125 0.06 0.125 0.25
C. krusei 120 8 2 4 8 2 2 8
A. fumigatus ATCC MYA-3626 1 0.25 0.5 0.25 0.06 0.125 1
A. fumigatus 676 4 1 1 1 0.125 0.25 4
A. fumigatus 88 2 0.5 1 0.5 0.125 0.125 2
L-AMB, liposomal amphotericin B; RIF, Rifampicin; AZM, Azithromycin; CLR, Clarithromycin; CST, Colistin; TET, Tetracycline; LZD, Linezolid.
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FIGURE 1 | Effect of liposomal amphotericin B (L-AMB) in combination with colistin upon C. albicans (strain 596) physiological parameters.
(A) Viability assessment by colony forming units (CFU) enumeration of C. albicans cells exposed to () L-AMB, () CST, and () L-AMB in association with CST. The
CFU counts of cells non-treated are represented as (). (B) Cell membrane potential was evaluated using DiBAC4(3) staining. (C) Cell membrane integrity was
evaluated using propidium iodide (PI) staining. (D) Cell metabolic activity was evaluated using 5-CFDA staining. Data at respective time points corresponds to
mean ± standard deviation. ∗p-values < 0.05, significant differences between the treatments with L-AMB alone and CST alone vs. the control (non-treated cells);
and between the association L-AMB/CST and L-AMB alone.
signal. The results obtained regarding membrane depolarization
ofC. albicans 596 are depicted in Figure 1B; after 3 h of treatment,
the SI of cells exposed to L-AMB 0.125 mg/L was 2.65 (p= 0.173);
at 6 h, the SI increased to 3.88 (p = 0.043), remaining constant
up to 24 h (p = 0.042). Whenever yeast cells were exposed to
CST, the SI was about 1.00 up to 6 h of treatment (p = 0.082),
increasing to 2.36 at 24 h (p = 0.052). Regarding the association
of L-AMB 0.125 mg/L with CST 3 mg/L, soon after 1 h of
treatment the SI was 3.79, increasing up to 14.38 following 24 h.
Significant differences were observed between the association
L-AMB/CST and single L-AMB at 1 h (p= 0.025), 3 h (p= 0.028),
6 h (p = 0.011), and 24 h (p = 0.011). L-AMB 0.125 mg/L in
association with CST 1.5 mg/L induced an increase of SI up to
24 h (SI = 6.69; p = 0.028). This effect was more pronounced
when L-AMB 0.125 mg/L was combined with CST 3 mg/L, as
previously described. However, when L-AMB 0.125 mg/L was
combined with CST 6 mg/L no significant differences were found,
compared to the association L-AMB/CST (3 mg/L; data not
shown).
Such results show the key role of L-AMB/CST association on
the increase of cell membrane depolarization.
Conversely, PI is a cell viability marker, which enters cells only
when membrane has been seriously injured. The results regarding
membrane lesion of C. albicans 596 are represented in Figure 1C.
In cells treated with L-AMB 0.125 mg/L, the % of PI(+) cells
after 1 h of exposure was about 10.00%, increasing slightly up
to 24 h (% of PI(+) cells = 14.93); significant differences were
found at 1 h (p= 0.019), 3 h (p= 0.036), 6 h (p= 0.008), and 24 h
(p= 0.036), compared to control (non-treated cells). Cells treated
with COL 3 mg/L showed PI-uptake only after 24 h of incubation,
with a % of PI(+) cells equal to 5.93 (p = 0.046). Concerning
the L-AMB/CST association, soon after 1 h of exposure, PI stains
21.82% of the treated cells, and after 6 h of incubation, this value
reaches 39.47%; at 24 h, the percentage of cells with membrane
lesion was about 45.01%. Significant differences were observed
between the L-AMB/CST association and L-AMB treatment at
1 h (p = 0.011), 3 h (p = 0.008), 6 h (p = 0.002), and 24 h
(p = 0.040). Thus, data suggests that L-AMB/CST association
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promotes the membrane lesion effect of L-AMB, in a time-
dependent fashion.
Metabolic Activity
To assess the metabolic effects of L-AMB/CST upon C. albicans
596, the cells were stained with 5-CFDA; 5-CFDA is a cell-
permeant esterase substrate that measures enzymatic activity
(Breeuwer et al., 1995; Boender et al., 2011). Only the cells
metabolically active will display a high level of fluorescence.
The results obtained for MIF are detailed in Figure 1D. MIF
displayed by viable cells (not exposed to the drugs) remained
constant up to 24 h; at this time point, the MIF was 176.99.
Cells treated with L-AMB did not display significant differences
in MIF up to 3 h (p = 0.198). After 6 h, MIF decreased over
time up to 75.53 (p = 0.049) at 24 h of exposure. When yeast
cells were treated only with CST 3 mg/L, the MIF increased
after 1 h (322.59; p = 0.029), indicating that the cells were
metabolically active. However, after 3 h of treatment, the MIF
decreased up to a value of 172.11 (p = 0.220), at 24 h, similar
to the MIF of cells not exposed to the drugs. Cells exposed to
the association L-AMB/CST initially displayed a very high MIF
(724.30); however, it decreased until 24 h of treatment (234.91).
Significant differences were registered between the metabolic
activity of cells exposed to the drug association and to L-AMB
alone at 1 h (p= 0.001), 3 h (p= 0.021), 6 h (p= 0.014), and 24 h
(p= 0.025).
Endogenous ROS Production
Reactive oxygen species production was assessed by DCFH-
DA staining. DCFH-DA is oxidized to highly fluorescent 2′,7′-
dichlorodihydrofluorescein (DCF) by ROS. ROS production by
cells exposed to L-AMB 0.125 mg/L was constant up to 6 h
of incubation (≈7.00%; p = 0.005); at 24 h, the number of
fluorescent cells increased up to 18% (p = 0.001) (Figure 2A).
Exposure to CST 3 mg/L resulted in reduced ROS formation
in C. albicans 596 cells, reaching a value of 7.00% (p = 0.010),
following a 24 h of incubation. Images obtained by fluorescence
microscopy (Figure 2B) showed vesicle formation in the presence
of CST, after 24 h of incubation. Cells exposed to L-AMB/CST
displayed a growing ROS production pattern; 7.00% following
6 h (p = 0.056); 25.53% following 24 h of incubation (p = 0.022)
(Figure 2A). These results reveal that L-AMB/CST leads to an
increase of intracellular accumulation of ROS in relation to single
L-AMB after 24 h.
Self-Association Propensity Assessed by
Atomic Molecular Dynamics Simulations
It is known the propensity of AMB to form dimeric or even
higher complex tetrameric structures once in water medium,
which interfere with the electrophysiology of living cells through
transmembrane ion channel formation (Starzyk et al., 2014).
Herein, we describe the propensity of AMB and CST in water
also to self-assembly based on MDs simulations. The results
demonstrate that the two molecules tend spontaneously form a
natural complex in solution, starting from a perfect unbound,
solvated form, separated by more than 17 Å. Once the two
molecules meet each other after the first 4 ns of simulation, they
FIGURE 2 | Effect of L-AMB in association with colistin upon
endogenous ROS production. (A) Endogenous reactive oxygen species
(ROS) production determined by DCFH-DA staining, assessed by flow
cytometry. (B) Fluorescence microscopy imaging showing ROS-positive cells
after treatment with (b) L-AMB and (c) CST alone and (d) in association after
24 h of exposure; (a) control, non-treated cells. ∗p-values < 0.05, significant
differences between the treatments with L-AMB alone and CST alone vs. the
control (non-treated cells); and between the association L-AMB/CST and
L-AMB alone.
are steadily attracted into a complex formation that stands stable
for the rest of the simulation time. This complex is characterized
by polar interactions, namely hydrogen bond interactions
between the C5- and C9-OH groups of AMB and amide groups
of CST, as depicted in Figures 3A,B. These two H-bond pairs
(AMB-O58:CST-N18 and AMB-O66:CST-O9) converged for a
minimum distance of 2.7 and 2.5 Å, respectively. It seems that
the complex is quite stable on the simulation window, supporting
an analogous mechanism to the one predicted and validated
experimentally for the dimerization of AMB alone. However,
the main dimer-stabilizing contacts of the AMB:CST system
seems to be the polar interactions and not the van der Waals
forces contribution, as described for the hydrophobic nature
of dimerization process of AMB molecules, which still might
be essential for speeding up transmembrane intercalation of
the complex and consequent disruption of the cell membrane
through pore formation, resulting into a perfect and synergetic
Trojan mechanism for the antimicrobial internalization (Starzyk
et al., 2014).
DISCUSSION
This study demonstrates that all the tested antibacterial agents
except linezolid interact synergistically with L-AMB against
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FIGURE 3 | Self-assembly of amphotericin B (AMB) and colistin (CST; represented in sticks) in water medium (represented in lines) through molecular
dynamics (MD) simulation studies. (A) Complex conformation snapshot after 20 ns of simulation, including water molecules within 4 Å of the complex. (B) Time
evolution of the h-bond distance between two molecules during the complex formation.
several pathogenic fungi, namely C. albicans, C. glabrata,
C. krusei, and A. fumigatus (Table 1). These antibacterial agents
alone did not exhibit antifungal activity, thus suggesting that
such compounds do not intrinsically target the fungal cells.
The agents tested belong to distinct antibacterial classes with
different mechanisms of action. Rifampicin inhibits the DNA-
dependent RNA polymerase (RNAP), leading to the suppression
of RNA synthesis and cell death (Campbell et al., 2001).
The basic architecture of bacterial RNAP and yeast RNAP
presents several structural differences (Minakhin et al., 2001),
explaining why RIF by itself does not display antifungal activity.
Azithromycin and CLR are macrolide antibiotics that bind
to 50S ribosomal subunits of bacteria, blocking the protein
synthesis and inhibiting cell growth (Kanoh and Rubin, 2010;
Parnham et al., 2014); LZD also binds to the 50S subunit of
the prokaryotic ribosome, blocking the assembly of a functional
initiation complex for protein synthesis (Livermore, 2003); TET
inhibits protein translation in bacteria by binding to the 30S
ribosomal subunit (Chopra and Roberts, 2001). Although the
basic mechanism of protein synthesis in eukaryotes is similar
to that in bacteria, some noteworthy differences were described
between the structure of eukaryotic and prokaryotic ribosomes
(Berg et al., 2002). Colistin belongs to the family of polymyxin
antibiotics, which target bacterial cell membrane. CST displaces
Mg2+ and Ca2+ ions, which stabilize the negatively charged
lipopolysaccharide LPS, disrupting the membrane integrity
in gram-negative bacteria (Falagas and Kasiakou, 2005). The
antifungal activity of polymyxin antibiotics against several fungal
species has been previously reported (Schwartz et al., 1972);
however, at the hereby tested concentrations, CST did not inhibit
fungal growth. Colistin plasma concentrations usually range from
0 to 15 mg/L, with free CST levels ranging from 0.5 to 3 mg/L
(Akers et al., 2015). It is important to emphasize that about 50%
of CST molecules bind to plasma proteins (Falagas and Kasiakou,
2005).
Considering all the antibiotic drug combinations evaluated,
the one that resulted in the strongest synergic effect was
L-AMB/CST. Additionally, the synergistic combination of CST
with other antifungal agents, namely echinocandins class, has
been previously described (Zeidler et al., 2013). Therefore, we
explored the underlying mechanism of synergism of L-AMB/CST
interaction.
Amphotericin B is a lifesaving antifungal drug used to
treat deep-seated fungal infections, exhibiting broad-spectrum
fungicidal activity. This activity is based on its interactions with
fungal cell membranes (Starzyk et al., 2014). AMB primarily
binds to ergosterol, inserts into the cytoplasmic membrane, and
forms pore-like structures; the result is osmotic instability, loss
of membrane integrity, metabolic disruption, and ultimately cell
death (Gray et al., 2012). Our results showed a significant growth
reduction of fungal cells treated with L-AMB/CST during 24 h
of exposure (108 to 105 cells/mL), with a simultaneous increase
of cell membrane permeability, as documented by DiBAC4(3)
(SI was 14.38) and PI staining (% of PI(+) cells was 45.01%)
(Figures 1B,C). Altogether, these results strongly indicate that the
association of CST significantly improves the fungicidal activity
of L-AMB.
It is known that yeast cells exposed to L-AMB pressure
reprogram their metabolism in response to an environmental
stress (Zhang et al., 2002; Belenky et al., 2013; Teixeira-
Santos et al., 2015). The combination of L-AMB and CST
triggered an increase of metabolic activity in treated cells, soon
after 1 h of exposure (3.8-fold higher than single L-AMB
treatment; Figure 1D), suggesting an early strong stress response
induced by membrane permeabilization. Along 24 h of exposure,
the metabolic activity decreased overtime, nevertheless, still
exhibiting a MIF 3.1-fold higher than single L-AMB treatment
(Figure 1D). This decrease can be explained by membrane pore
formation, which may cause the accelerated loss of fluorescence,
or by a reduced metabolic activity (Breeuwer et al., 1995; Teixeira-
Santos et al., 2015). Interestingly, the higher cell metabolic
activity induced by the association of L-AMB/CST versus single
L-AMB along 24 h period can be related with a higher
endogenous ROS production in cells exposed to this association
(Figure 2), which will result in oxidative damage and possibly is
involved in induced programmed cell death (Phillips et al., 2003;
Al-Dhaheri and Douglas, 2010). Curiously, single CST (3 mg/L)
has a significant effect on ROS production by itself. Accordingly,
cells exposed to CST display a different phenotype compared to
cells exposed to the other treatment conditions, i.e., the formation
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of vesicles (apoptotic bodies), which is a characteristic event of
apoptosis (Fink and Cookson, 2005). Although the functional
studies that support the mechanism of action of L-AMB/CST
association have been conducted only in C. albicans, according
to the MIC determination assays, this mechanism seems to be
transversal to the different species studied.
All of our results point to a considerable improvement
of L-AMB antifungal effect, at subinhibitory concentrations,
whenever associated to CST 3 mg/L. However, how do AMB and
CST molecules interact? The computational molecular dynamics
results demonstrate that the two molecules spontaneously form
a natural complex in solution, characterized by a strong bond
1:1. Thus, AMB and CST molecules act together on fungal
cells. In support of such a finding was the fact that the
maximum synergistic effect was detected in the presence of peak
plasma concentration of CST (3 mg/L); its increase to fourfold
peak plasma concentration did not increase the synergistic
effect, as documented by MIC determination and membrane
potential evaluation assays. Moreover, a recent study described
that the interactions of AMB with biomembranes are managed
by the molecular organization of AMB (Starzyk et al., 2014).
AMB self-associates to dimeric structures; AMB dimers can
further assemble into tetramers, which induce the formation of
transmembrane ion channels, impairing the electrophysiological
homeostasis of a living cell (Starzyk et al., 2014; Davis et al., 2015).
Considering all these findings, it is possible that CST binds to
AMB molecules and accelerates the assembly of AMB tetramers,
thus inducing pore formation on fungal cell membranes, also
triggering a strong cell stress response, which is typical of AMB
action.
Our results are extremely promising since AMB is an
important therapeutic alternative for the treatment of IFIs,
particularly when infection persists, despite treatment with other
drugs, and the clinical response to AMB is reduced in about
40% of treated patients (Mora-Duarte et al., 2002; Ito and
Hooshmand-Rad, 2005; Park et al., 2006). Simultaneously, this
synergic association may be a clue for drug discovery.
Studies are being conducted in order to characterize the
functional groups of the AMB/CST complex that interact with
the fungal membrane aiming to design a more active antifungal
compound.
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